Evogene Ltd. EVGN
0.36 USD 0.00 (+0.06%)
Nov 3, 2026, 2:42 PM EST
0.3524 Day range 0.3898
0.35 52-week range 1.28
- YTD
- -67.16%
- 1 year
- -71.33%
Analyst view
Price target (mean) 8.13 +2149.4% upside
Now 0.3612
- Target (low)
- 5.00
- Target (mean)
- 8.13
- Target (high)
- 11.25
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 2
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.725 | -0.76 – -0.69 | -1.30 | +44.2% | 3.63M | +527.2% | 2 |
| Next quarter | -0.73 | -0.73 – -0.73 | -0.80 | +8.8% | 4.00M | -4.5% | 1 |
| Current year | -4.12 | -4.35 – -3.88 | -5.20 | +20.9% | 10.53M | +86.6% | 2 |
| Next year | -3.11 | -3.20 – -3.02 | -4.12 | +24.4% | 14.60M | +38.7% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 23, 2024 | Lake Street | Maintained | Buy | Buy |
| Oct 2, 2023 | Alliance Global Partners | Initiated | — | Buy |
| Aug 18, 2023 | Lake Street | Maintained | Buy | Buy |
| Jul 21, 2023 | Roth MKM | Maintained | Buy | Buy |
| May 2, 2023 | Lake Street | Initiated | — | Buy |
| Sep 12, 2022 | Aegis Capital | Maintained | — | Buy |
| Sep 2, 2022 | Roth MKM | Maintained | Buy | Buy |
| Oct 8, 2021 | Roth Capital | Initiated | — | Buy |
| Jul 29, 2021 | Aegis Capital | Initiated | — | Buy |
| Dec 1, 2020 | Cantor Fitzgerald | Initiated | — | Overweight |